"The MHC franchise offers health-care professionals the first evidence-based approach to successfully treat patients with erectile dysfunction and/or testosterone deficiency syndrome (androgen deficiency in adult male - ADAM), even those with underlying medical conditions", stated Piroska De Jesus, regional MHC franchise manager.
Dr Farid Saad, head of scientific affairs of Bayer Schering Pharma in Germany, addressed the relationship between testosterone deficiency and metabolic syndrome. Based on clinical studies, these conditions are closely related and seriously affect the quality of life of the adult male. Currently, the new MHC franchise embraces two products: Levitra, the treatment for erectile dysfunction with the fastest onset of action and superior side effects profile; and Nebido, the first quarterly testosterone injection that improves sexual function, muscle strength, libido and mood, which are conditions associated with ADAM.
Source: Bayer Schering Pharma